

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>McKew John C.</u>			2. Date of Event Requiring Statement (Month/Day/Year) <u>03/18/2020</u>		3. Issuer Name and Ticker or Trading Symbol <u>LUMOS PHARMA, INC. [(LUMO)]</u>		
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ <u>Chief Scientific Officer</u>			5. If Amendment, Date of Original Filed (Month/Day/Year)	
4200 MARATHON BLVD SUITE 200			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person				
(Street)	(City)	(State)	(Zip)				
AUSTIN	TX		78756				

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	03/04/2017 ⁽¹⁾	07/11/2026	Common Stock	81,690	4.82	D	
Stock Option (Right to Buy)	12/05/2018 ⁽²⁾	01/18/2028	Common Stock	9,583	2.45	D	
Stock Option (Right to Buy)	08/29/2018 ⁽³⁾	08/29/2028	Common Stock	6,541	2.45	D	

Explanation of Responses:

- The shares subject to the option became fully vested and exercisable March 4, 2020.
- One-fourth of the shares subject to the option vested and became exercisable on December 5, 2018, and thereafter the remainder of the shares subject to the option continue to vest in 36 substantially equal monthly installments, subject to the reporting person's continued service with the Issuer and subject to acceleration upon the occurrence of certain events.
- The shares subject to the option became fully vested and exercisable on the grant date, August 29, 2018.

Remarks:

/s/ Ryan Trytten, attorney-in-fact

03/30/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR SECTION 16(a) REPORTING

KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints each Carl W. Langren, Lori Lawley, Bradley J. I

1. prepare, execute, deliver and file with the United States Securities and Exchange Commission, any national securities exchange and the C
2. seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's equity

The undersigned acknowledges that:

1. this Limited Power of Attorney authorizes, but does not require, the Attorney-in-Fact to act at his or her discretion on information pro
2. any documents prepared and/or executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this Limited Power of Attorney w
3. neither the Company nor the Attorney-in-Fact assumes any liability for the undersigned's responsibility to comply with the requirements
4. this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations un

The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing requisite, neces:

IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney for Section 16(a) Reporting to be executed as of March 18, 2020.

Signature: /s/ John McKew

Print Name: John McKew